• Nicotinamide Riboside Chloride in RGC Assays

  2026-09-10

  Nicotinamide Riboside Chloride (NIAGEN) can add a precisely controllable NAD+ dimension to retinal ganglion cell experiments. This article explains how to use it as an assay variable without confusing metabolic rescue with differentiation, identity, or neuronal function.

• How Simvastatin Reshapes Phospholipid Bilayers

  2026-09-10

  The reference study uses all-atom molecular dynamics simulations to compare neutral lactone and active anionic forms of Simvastatin in POPC and POPC/cholesterol membranes. Its central finding is that membrane composition and drug ionization state jointly determine bilayer localization, ordering, and fluidity, providing a mechanistic framework for interpreting statin membrane effects without equating simulation results with clinical toxicity.

• How Mixing Changes mRNA Lipid Nanoparticle Performance

  2026-09-09

  The reference study isolates primary mixing as a major determinant of mRNA lipid nanoparticle physicochemical properties and biological performance. By comparing ten mixing approaches under otherwise controlled formulation conditions, it shows why manually mixed or laboratory-scale particles may not predict products made with turbulent-flow equipment at manufacturing scale.

• Vorinostat: From Chromatin to Translational Insight

  2026-09-09

  Vorinostat (SAHA, MK0683) is more than a cytotoxic screening reagent. This thought-leadership analysis connects HDAC inhibition, chromatin remodeling, intrinsic apoptosis, and emerging insights into RNA polymerase II-linked cell death, while offering practical guidance for cancer biology research, cutaneous T-cell lymphoma models, and translational assay design.

• MDM1, p53, and Chemoradiotherapy Sensitivity in CRC

  2026-09-08

  The reference study identifies MDM1 as a functional determinant of colorectal cancer chemoradiotherapy response, linking MDM1 expression to YBX1-dependent control of TP53, apoptosis, and treatment sensitivity. Its combination of patient-associated profiling, gain- and loss-of-function experiments, transcriptomics, and xenograft validation supports MDM1 as a candidate predictive biomarker while also defining important limits for clinical translation.

• Measuring Cancer Drug Responses Beyond Viability

  2026-09-08

  Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer response. Its central practical implication is that drug-induced growth inhibition and cell death should be measured and interpreted as related but temporally distinct outcomes.

• PD0325901: MEK Inhibition in Cancer Research

  2026-09-07

  PD0325901 is a selective MEK inhibitor that reduces ERK phosphorylation and provides a research tool for studying RAS/RAF/MEK/ERK signaling pathway inhibition. Product information reports cell-cycle effects and tumor growth suppression in mouse xenograft models, while recent human stem-cell research links MEK/ERK activity to TERT transcription and chromatin state.

• a-MSH, amide: Designing Causal Assays

  2026-09-07

  Learn how a-MSH, amide and alpha-melanocyte-stimulating hormone amide can anchor causal assays for pigmentation, inflammation, and receptor pharmacology. This guide connects MC1R perturbation with orthogonal endpoint selection and practical interpretation of CREB/MITF evidence.

• Neuritin and ER Stress After Subarachnoid Hemorrhage

  2026-09-05

  The reference study identifies three endoplasmic-reticulum-stress-associated routes that converge on NF-κB to link early neuroinflammation with neuronal apoptosis after subarachnoid hemorrhage. Its central innovation is showing that neuritin overexpression suppresses these pathways, providing a mechanistic framework for interpreting neuroprotective effects in early brain injury while highlighting the need for pathway-specific validation.

• Magnetic Stimulation Targets GABRE in Schizophrenia-Like Mic

  2026-09-04

  This Molecular Psychiatry study identifies the GABAA receptor epsilon subunit, GABRE, in the left prelimbic cortex as a mechanistically relevant target of selective magnetic stimulation. Using pharmacological, genetic, behavioral, and synaptic approaches, the authors show that GABRE reduction is associated with recovery from MK-801-induced schizophrenia-like phenotypes and may involve p62/SQSTM1-mediated regulation of GABARAP proteins.

• DIDS: From Chloride Transport to Cell-Fate Assays

  2026-09-04

  DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) is more than a chloride-channel probe: it can connect membrane transport, stress survival, and cell-state analysis. This guide explains how to design better DIDS experiments while avoiding overinterpretation across vascular, neural, and tumor models.

• TSPAN18–STIM1 Signaling in Prostate Cancer Bone Metastasis

  2026-09-03

  Zhou et al. identify TSPAN18 as a previously unrecognized regulator of STIM1 stability in prostate cancer. By limiting TRIM32-mediated ubiquitination, TSPAN18 strengthens STIM1-dependent calcium entry and promotes metastatic behaviors, providing a mechanistic link between protein turnover, calcium signaling, and bone colonization.

• How Wnt Rewires Glycolysis for Bone Formation

  2026-09-03

  The reference study identifies O-GlcNAcylation as a metabolic relay that connects Wnt3a stimulation with PDK1 stabilization, aerobic glycolysis, and osteoblast-driven bone formation. Its experimental framework shows how pathway activation can be analyzed across signaling kinetics, protein modification, glucose metabolism, and in vivo fracture repair.

• THZ1 Workflow for Covalent CDK7 Inhibition

  2026-09-02

  THZ1 is a covalent CDK7 inhibitor for testing transcriptional dependence, selective cancer-cell vulnerability, and apoptosis-linked growth suppression. This workflow connects T-ALL experiments with a carefully bounded adipogenesis application inspired by super-enhancer research, while emphasizing controls, washout design, and compound-handling precision.

• Bufuralol Hydrochloride in Organoid PK Assays

  2026-09-02

  Bufuralol hydrochloride offers a useful challenge compound for connecting intestinal disposition with β-adrenergic pharmacology. This article presents a decision-focused framework for applying hiPSC-derived intestinal organoids without confusing pharmacokinetic readouts with receptor-specific cardiovascular effects.

8316 records 1/555 page Next 12345 下5页 Last page